Allogene Therapeutics, Inc. Forecast, price target & analysts
Allogene Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Allogene Therapeutics, Inc. Classifications & Recommendation
Allogene Therapeutics, Inc. Price Target
| Target Price | $9.18 |
| Price | $1.63 |
| Potential |
463.19%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Allogene Therapeutics, Inc. 2027 .
The average Allogene Therapeutics, Inc. target price is $9.18.
This is
463.19%
register free of charge
$14.70
801.84%
register free of charge
$4.04
147.85%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend Allogene Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Allogene Therapeutics, Inc. stock has an average upside potential 2027 of
463.19%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 4.28 |
| 100.00% |
13 Analysts have issued a sales forecast Allogene Therapeutics, Inc. 2026 . The average Allogene Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Allogene Therapeutics, Inc. EBITDA forecast 2026. The average Allogene Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Allogene Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Allogene Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.87 | -0.63 |
| 34.09% | 27.59% | |
| P/E | negative | |
| EV/Sales | 53.82 |
15 Analysts have issued a Allogene Therapeutics, Inc. forecast for earnings per share. The average Allogene Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Allogene Therapeutics, Inc....
Current Allogene Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citizens |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Apr 16 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 16 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 15 2026 |
| Argus Research |
Locked
➜
Locked
|
Locked | Apr 14 2026 |
| Baird |
Locked
➜
Locked
|
Locked | Apr 14 2026 |
| Bernstein |
Locked
➜
Locked
|
Locked | Apr 14 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Apr 16 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 16 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 15 2026 |
|
Locked
Argus Research:
Locked
➜
Locked
|
Apr 14 2026 |
|
Locked
Baird:
Locked
➜
Locked
|
Apr 14 2026 |
|
Locked
Bernstein:
Locked
➜
Locked
|
Apr 14 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
